ADAMTS5

ADAMTS5 Full Name

ADAM metallopeptidase with thrombospondin type 1 motif, 5

ADAMTS5 Introduction

ADAMTS5 (ADAM metallopeptidase with thrombospondin type 1 motif 5), also known as aggrecanase-2, is a secreted zinc-dependent protease belonging to the ADAMTS family that plays a central role in extracellular matrix (ECM) remodeling. For patients and researchers facing progressive cartilage degeneration, especially in osteoarthritis (OA), ADAMTS5 represents one of the most critical molecular drivers behind irreversible tissue breakdown. It is synthesized as an inactive zymogen in chondrocytes and processed through the endoplasmic reticulum–Golgi secretory pathway, where it is subsequently activated by furin-mediated cleavage in the extracellular environment. Once activated, ADAMTS5 localizes to the ECM and specifically targets aggrecan, a key structural proteoglycan responsible for cartilage resilience, cleaving it at defined Glu–Xaa sites. This tightly regulated enzymatic activity is normally controlled by endogenous inhibitors such as TIMP3, which forms complexes with ADAMTS5 and promotes receptor-mediated clearance via LRP-1, maintaining tissue homeostasis under physiological conditions.

Functionally, ADAMTS5 is not merely a degradative enzyme but a highly regulated mediator of tissue turnover. Under inflammatory or mechanical stress conditions, multiple signaling pathways—including NF-κB, Wnt/β-catenin, Notch, Runx2, FGF2, and YAP/TAZ—drive its overexpression and activation, shifting cartilage metabolism toward catabolism. Recent mechanistic studies further highlight that transcriptional regulation by SP1 significantly enhances ADAMTS5 expression in IL-1β-stimulated chondrocytes, amplifying downstream Wnt/β-catenin signaling and accelerating chondrocyte apoptosis and ECM degradation. Beyond cartilage, ADAMTS5 also processes other proteoglycans such as versican, indicating broader physiological relevance in vascular and cardiac tissue remodeling, where uncontrolled proteolysis may contribute to structural instability.

Clinically, dysregulated ADAMTS5 activity is most prominently associated with osteoarthritis, where it acts as a key aggrecanase driving early and progressive cartilage erosion. Elevated ADAMTS5 expression correlates with inflammatory cytokine exposure, aging-related tissue decline, genetic susceptibility, and abnormal biomechanical loading, all of which converge to accelerate joint degeneration. Importantly, preclinical studies have demonstrated that genetic knockdown, monoclonal antibodies, and small-molecule inhibitors targeting ADAMTS5 can significantly reduce cartilage breakdown and preserve joint integrity in experimental models. Emerging research also links ADAMTS5 to endothelial cell apoptosis via interaction with cell-surface nucleolin, suggesting additional roles in vascular pathology. These findings position ADAMTS5 as a high-value therapeutic target, particularly for patients suffering from OA who currently lack disease-modifying treatment options, highlighting its importance in next-generation anti-degenerative drug development.

Alternate Names for ADAMTS5

ADAMTS5; ADAM metallopeptidase with thrombospondin type 1 motif, 5; ADMP-2; ADAM-TS5; ADAMTS-5; ADAMTS11; ADAM-TS 5; ADAMTS-11; ADAM-TS 11; A disintegrin and metalloproteinase with thrombospondin motifs 5

• 1.Jiang L, et al.; ADAMTS5 in Osteoarthritis: Biological Functions, Regulatory Network, and Potential Targeting Therapies. Front Mol Biosci. 2021, 8:703110.
  2.Kirman DC, et al.; Cell surface nucleolin is a novel ADAMTS5 receptor mediating endothelial cell apoptosis. Cell Death Dis. 2022, 13(2):172.